Price chart
Loading 1Y daily…
Financial overlay · last 12 quarters
| Quarter | Revenue | Net income | Op income | FCF | Net margin | Op margin |
|---|---|---|---|---|---|---|
| 2026-03-31 | $11.2B | $1.1B | $1.3B | $0.9B | 9.6% | 12.0% |
| 2025-12-31 | $11.5B | $1.8B | $2.3B | $2.6B | 15.5% | 19.6% |
| 2025-09-30 | $11.4B | $1.6B | $2.1B | $2.3B | 14.5% | 18.1% |
| 2025-06-30 | $11.1B | $1.8B | $2.1B | $1.5B | 16.0% | 18.4% |
| 2025-03-31 | $10.4B | $1.3B | $1.7B | $0.9B | 12.8% | 16.3% |
Earnings replay · last 20 reports
| Date | EPS actual | EPS est | Surprise |
|---|---|---|---|
| 2026-04-16 | 1.15 | 1.15 | +0.3% |
| 2026-01-22 | 1.50 | 1.49 | +0.3% |
| 2025-10-15 | 1.30 | 1.30 | +0.1% |
| 2025-07-17 | 1.01 | 0.99 | +1.9% |
| 2025-04-16 | 0.76 | 0.78 | -2.6% |
| 2025-01-22 | 1.34 | 1.34 | -0.2% |
| 2024-10-16 | 1.21 | 1.20 | +0.8% |
| 2024-07-18 | 1.14 | 1.10 | +3.2% |
| 2024-04-17 | 0.98 | 0.95 | +2.8% |
| 2024-01-24 | 1.19 | 1.19 | +0.0% |
| 2023-10-18 | 1.14 | 1.10 | +3.7% |
| 2023-07-20 | 1.08 | 1.05 | +2.9% |
| 2023-04-19 | 1.03 | 0.99 | +4.3% |
| 2023-01-25 | 1.03 | 0.94 | +9.7% |
| 2022-10-19 | 1.15 | 0.94 | +22.9% |
| 2022-07-20 | 1.43 | 1.14 | +25.3% |
| 2022-04-20 | 1.73 | 1.46 | +18.1% |
| 2022-01-26 | 1.32 | 1.21 | +9.5% |
| 2021-10-20 | 1.40 | 0.95 | +47.9% |
| 2021-07-22 | 1.17 | 1.02 | +14.9% |
Earnings markers are overlaid on the price chart above. Transcript summaries require PERPLEXITY_API_KEY (deferred to a follow-up).
Peer comparison · Healthcare
| Ticker ⇅ | Mkt cap ⇅ | P/E ⇅ | Fwd P/E ⇅ | P/S ⇅ | EV/EBITDA ⇅ | P/B ⇅ | Gross M ⇅ | Rev gr ⇅ | EPS gr ⇅ | FCF yld ⇅ |
|---|---|---|---|---|---|---|---|---|---|---|
| LLY | $949B | 37.7 | 23.9 | 13.1 | 27.3 | 30.5 | 82.8% | 55.5% | 169.9% | 0.96% |
| UNH | $343B | 28.5 | 18.1 | 0.8 | 18.5 | 3.5 | 18.8% | 2.0% | 0.7% | 5.15% |
| JNJ | $537B | 25.8 | 17.5 | 5.6 | 16.6 | 6.6 | 68.0% | 9.9% | -52.9% | 2.33% |
| MRK | $286B | 32.6 | 12.1 | 4.3 | 11.2 | 6.2 | 76.7% | 4.9% | — | 4.92% |
| ABBV | $381B | 105.1 | 13.3 | 6.1 | 14.8 | -57.2 | 72.0% | 12.4% | -46.2% | 5.47% |
| PFE | $146B | 19.5 | 9.0 | 2.3 | 7.8 | 1.6 | 74.8% | 5.4% | -10.1% | 8.50% |
| TMO | $179B | 26.5 | 17.7 | 4.0 | 19.4 | 3.4 | 40.9% | 6.2% | 11.3% | 3.08% |
| ABT ★ | $151B | 24.4 | 14.3 | 3.4 | 15.2 | 2.9 | 56.5% | 7.8% | -19.7% | 4.19% |
Auto-seeded from sector. Click any ticker to switch.
Ownership
Top institutional holders
Top-10 concentration: 35.31%
| Holder | Shares | % out |
|---|---|---|
| Blackrock Inc. | 145,687,458 | 8.36% |
| Vanguard Capital Management LLC | 112,949,933 | 6.48% |
| State Street Corporation | 79,575,468 | 4.57% |
| Capital Research Global Investors | 49,775,362 | 2.86% |
| Vanguard Portfolio Management LLC | 47,944,891 | 2.75% |
| Charles Schwab Investment Management | 45,500,055 | 2.61% |
| Geode Capital Management, LLC | 39,148,795 | 2.25% |
| Capital International Investors | 37,498,227 | 2.15% |
| Morgan Stanley | 30,101,596 | 1.73% |
| Wellington Management Group, LLP | 27,070,518 | 1.55% |
Insider activity · 90d
No insider trades for ABT in last 90d.
Analyst estimates
yfinanceConsensus: buy (mean 1.66667). Distribution requires FINNHUB_API_KEY.
SEC filings
| Form | Filed | Description | Action |
|---|---|---|---|
| 4 | 2026-04-29 | Insider transaction (Form 4) | view · |
| 10-Q | 2026-04-29 | 10-Q | view · |
| 4 | 2026-04-28 | Insider transaction (Form 4) | view · |
| 4 | 2026-04-28 | Insider transaction (Form 4) | view · |
| 4 | 2026-04-28 | Insider transaction (Form 4) | view · |
| 4 | 2026-04-28 | Insider transaction (Form 4) | view · |
| 4 | 2026-04-28 | Insider transaction (Form 4) | view · |
| 4 | 2026-04-28 | Insider transaction (Form 4) | view · |
| 4 | 2026-04-28 | Insider transaction (Form 4) | view · |
| 4 | 2026-04-28 | Insider transaction (Form 4) | view · |
| 4 | 2026-04-28 | Insider transaction (Form 4) | view · |
| 4 | 2026-04-28 | Insider transaction (Form 4) | view · |
| 4 | 2026-04-28 | Insider transaction (Form 4) | view · |
| 4 | 2026-04-28 | Insider transaction (Form 4) | view · |
| 4 | 2026-04-27 | Insider transaction (Form 4) | view · |
| 8-K | 2026-04-27 | FORM 8-K | view · |
| 8-K | 2026-04-17 | FORM 8-K | view · |
| 8-K | 2026-04-16 | 8-K | view · |
| 4 | 2026-04-02 | Insider transaction (Form 4) | view · |
| 4 | 2026-04-02 | Insider transaction (Form 4) | view · |
| 4 | 2026-04-02 | Insider transaction (Form 4) | view · |
| 4 | 2026-04-02 | Insider transaction (Form 4) | view · |
| 4 | 2026-04-02 | Insider transaction (Form 4) | view · |
| 4 | 2026-03-25 | Insider transaction (Form 4) | view · |
| 8-K | 2026-03-23 | FORM 8-K | view · |
| DEF 14A | 2026-03-13 | DEFINITIVE PROXY STATEMENT | view · |
| 8-K | 2026-03-09 | FORM 8-K | view · |
| 4 | 2026-03-03 | Insider transaction (Form 4) | view · |
| 4 | 2026-03-03 | Insider transaction (Form 4) | view · |
| 4 | 2026-03-03 | Insider transaction (Form 4) | view · |
| 4 | 2026-03-03 | Insider transaction (Form 4) | view · |
| 4 | 2026-03-03 | Insider transaction (Form 4) | view · |
| 4 | 2026-03-03 | Insider transaction (Form 4) | view · |
| 4 | 2026-03-03 | Insider transaction (Form 4) | view · |
| 4 | 2026-03-03 | Insider transaction (Form 4) | view · |
| 4 | 2026-03-03 | Insider transaction (Form 4) | view · |
| 4 | 2026-03-03 | Insider transaction (Form 4) | view · |
| 4 | 2026-02-26 | Insider transaction (Form 4) | view · |
| 4 | 2026-02-26 | Insider transaction (Form 4) | view · |
| 4 | 2026-02-26 | Insider transaction (Form 4) | view · |
| 4 | 2026-02-26 | Insider transaction (Form 4) | view · |
| 4 | 2026-02-26 | Insider transaction (Form 4) | view · |
| 4 | 2026-02-26 | Insider transaction (Form 4) | view · |
| 4 | 2026-02-26 | Insider transaction (Form 4) | view · |
| 4 | 2026-02-26 | Insider transaction (Form 4) | view · |
| 4 | 2026-02-26 | Insider transaction (Form 4) | view · |
| 4 | 2026-02-26 | Insider transaction (Form 4) | view · |
| 8-K | 2026-02-26 | FORM 8-K | view · |
| 8-K | 2026-02-20 | FORM 8-K | view · |
| 10-K | 2026-02-20 | 10-K | view · |
| 4 | 2026-02-06 | Insider transaction (Form 4) | view · |
| 4 | 2026-01-26 | Insider transaction (Form 4) | view · |
| 8-K | 2026-01-22 | 8-K | view · |
| 4 | 2026-01-05 | Insider transaction (Form 4) | view · |
| 4 | 2026-01-05 | Insider transaction (Form 4) | view · |
| 4 | 2026-01-05 | Insider transaction (Form 4) | view · |
| 4 | 2026-01-05 | Insider transaction (Form 4) | view · |
| 4 | 2025-12-12 | Insider transaction (Form 4) | view · |
| 8-K | 2025-12-12 | FORM 8-K | view · |
| 4 | 2025-11-25 | Insider transaction (Form 4) | view · |
About
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood ga…